Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Inventory (2016 - 2025)

Amphastar Pharmaceuticals has reported Inventory over the past 13 years, most recently at $176.9 million for Q4 2025.

  • Quarterly results put Inventory at $176.9 million for Q4 2025, up 15.06% from a year ago — trailing twelve months through Dec 2025 was $176.9 million (up 15.06% YoY), and the annual figure for FY2025 was $176.9 million, up 15.06%.
  • Inventory for Q4 2025 was $176.9 million at Amphastar Pharmaceuticals, down from $185.9 million in the prior quarter.
  • Over the last five years, Inventory for AMPH hit a ceiling of $191.7 million in Q2 2025 and a floor of $92.8 million in Q4 2021.
  • Median Inventory over the past 5 years was $105.2 million (2023), compared with a mean of $123.7 million.
  • Biggest five-year swings in Inventory: fell 10.0% in 2021 and later surged 60.59% in 2025.
  • Amphastar Pharmaceuticals' Inventory stood at $92.8 million in 2021, then rose by 11.61% to $103.6 million in 2022, then increased by 2.17% to $105.8 million in 2023, then skyrocketed by 45.27% to $153.7 million in 2024, then rose by 15.06% to $176.9 million in 2025.
  • The last three reported values for Inventory were $176.9 million (Q4 2025), $185.9 million (Q3 2025), and $191.7 million (Q2 2025) per Business Quant data.